GoBroad at ESMO 2026: New Directions in Cancer Treatment Research

Research presented at a major international oncology conference highlights emerging approaches to treating melanoma, colorectal cancer, brain tumours and other complex cancers.

What Is ESMO, and Why Does It Matter?

The European Society for Medical Oncology (ESMO) is a leading international professional organisation dedicated to advancing cancer research, treatment and patient care.

Its annual ESMO Congress brings together oncologists, researchers, healthcare institutions and pharmaceutical developers from around the world to share clinical trial findings and discuss developments in cancer medicine.

At ESMO Congress 2026, China’s GoBroad Healthcare Group (GHG) and its collaborating research teams reported 38 scientific contributions, including three late-breaking abstracts, six oral presentations and 29 poster and electronic poster presentations.

According to GoBroad’s ESMO 2026 special-edition newsletter, the research covered several emerging cancer treatment approaches, including tumour-infiltrating lymphocyte (TIL) therapy, CAR-T cell therapy, antibody-drug conjugates and molecularly targeted medicines.

For international patients, an important distinction must be made: presentation at ESMO does not automatically mean that a treatment has been approved, is routinely available or has demonstrated long-term clinical benefit.

The strength of the evidence depends on the study design, number of patients, results, safety findings and follow-up period.

TIL Therapy for Advanced Melanoma

One of the research developments highlighted by GoBroad involved GC101, an investigational tumour-infiltrating lymphocyte therapy for advanced melanoma.

TIL therapy involves collecting immune cells that have entered a patient’s tumour, expanding selected cells in a laboratory and administering them back to the patient as part of a specialised treatment programme.

GoBroad’s ESMO special edition reports Phase III findings for GC101, including median progression-free survival of 4.37 months, compared with 1.61 months in the comparator group.

Progression-free survival measures the period during which a patient’s cancer does not worsen according to the study’s assessment criteria. It does not necessarily indicate longer overall survival or a cure.

The newsletter also states that GC101 was undergoing regulatory review and had not received marketing approval at the time of publication.

Patients should therefore distinguish this investigational product from other TIL therapies that may have different regulatory status, clinical evidence and eligibility requirements.

GCC CAR-T Therapy for Colorectal Cancer

Another featured research area involves GCC-targeted CAR-T therapy for advanced colorectal cancer.

CAR-T therapy uses a patient’s T cells, which are modified to recognise a particular target associated with cancer cells.

CAR-T treatments have become established for certain blood cancers, but their application to solid tumours, including colorectal cancer, presents additional scientific and clinical challenges.

The GCC-targeted approach highlighted in GoBroad’s newsletter is part of ongoing research into whether engineered immune cells can recognise and attack selected colorectal cancer cells.

This remains an investigational strategy. Its potential benefits, safety profile and suitability for patients require evaluation through appropriately designed clinical trials.

Antibody-Drug Conjugates for Advanced Solid Tumours

GoBroad’s ESMO research programme also featured a CDH17-targeted antibody-drug conjugate (ADC) being studied in advanced solid tumours.

An antibody-drug conjugate combines an antibody designed to recognise a particular cellular target with an attached anticancer medicine.

The aim is to deliver the drug more selectively to cells expressing the target, although adverse effects and damage to healthy tissues can still occur.

CDH17 is a protein being investigated as a potential therapeutic target in certain cancers.

The research highlighted by GoBroad contributes to the wider development of targeted medicines, but individual patients should not assume that a CDH17-directed treatment is appropriate or clinically available for their diagnosis.

Targeted Research for Brain Tumours

The ESMO special edition also highlighted early-phase research involving HSK42360, an investigational brain-penetrant BRAF inhibitor for selected gliomas carrying a BRAF V600 mutation.

Gliomas are a group of tumours arising from cells in the brain or central nervous system. Their diagnosis and treatment depend on factors including tumour type, grade, molecular characteristics and previous treatment.

A medicine designed to reach the brain and act on a particular molecular alteration may offer a promising research direction for carefully selected patients.

However, Phase I studies are primarily concerned with questions such as safety, dosage and preliminary treatment activity. Larger studies and longer follow-up may be needed to establish clinical benefit.

This research complements GoBroad’s expansion of specialist neuro-oncology services in Beijing.

Read our related article: GoBroad Opens Comprehensive Neuro-Oncology Center in Beijing.

Other Research Highlighted at ESMO 2026

GoBroad’s special edition also describes research involving a bispecific antibody for advanced extrapulmonary neuroendocrine carcinoma.

Bispecific antibodies are designed to interact with two different biological targets. Depending on their design, they may help direct immune activity or interfere with processes involved in cancer growth.

Extrapulmonary neuroendocrine carcinoma is an uncommon and often aggressive form of cancer arising outside the lungs.

Research into new approaches is important because treatment options can be limited, particularly when disease progresses after established therapy.

Nevertheless, conference findings must be evaluated in the context of the complete study data, including treatment-related adverse events and the characteristics of participating patients.

What Should International Patients Take From These Developments?

For patients exploring specialist cancer care in China or elsewhere in Asia, the most useful question is not simply whether a hospital is researching a new treatment.

It is whether that treatment is appropriate, accessible and supported by sufficient clinical evidence for their individual condition.

Before pursuing an overseas consultation or clinical trial, patients should consider:

• Whether their diagnosis has been confirmed through appropriate pathology and molecular testing.
• Which established treatment options remain available.
• Whether the proposed treatment is approved, investigational or accessible only through a clinical trial.
• What evidence exists for benefits, risks and longer-term outcomes.
• Whether they meet the eligibility criteria for a particular programme.
• How treatment costs, travel requirements and follow-up care will be managed.

An independent specialist opinion may also help patients assess treatment proposals and avoid unnecessary travel.

For patients considering medical treatment overseas, our established sister platform, Medical Tourism Vietnam, provides further guidance on international patient enquiries, treatment planning and the importance of choosing appropriately qualified healthcare providers.

China’s Expanding Role in Specialist Cancer Research

GoBroad’s reported contributions to ESMO 2026 illustrate China’s growing participation in international oncology research, particularly in cellular immunotherapy, targeted medicines and precision oncology.

These developments are relevant to Glowcations Asia’s coverage of specialist healthcare and medical innovation across the region.

Explore our China healthcare and medical travel destination guide for further information about specialist services and considerations for international patients.

Our earlier feature, Medical Travel in Asia: Why Patient Trust Matters More Than Price, explains why provider credentials, transparent information, clinical evidence and continuity of care remain central to responsible medical travel.

For broader reporting on medical innovation, healthcare developments and their implications across Asia, readers can also visit our editorial publication, Hanoi Trading Post.

About GoBroad Healthcare Group

GoBroad Healthcare Group is a China-based healthcare organisation involved in specialist clinical services and medical research, including haematology, oncology and complex cancer care.

Its ESMO Congress 2026 special-edition newsletter summarises research presented by GoBroad and collaborating expert teams across several cancer types.

Editorial note: This article draws principally on GoBroad Healthcare Group’s ESMO Congress 2026 special-edition newsletter. Research findings and participation figures are attributed to GoBroad. Conference presentations may report preliminary or investigational findings and should not be interpreted as confirmation of regulatory approval, routine clinical availability or individual treatment suitability.

Medical information disclaimer: Glowcations Asia provides educational information about healthcare developments and international patient services. It does not diagnose medical conditions, prescribe treatments or determine clinical trial eligibility. Patients should discuss treatment decisions with appropriately qualified medical specialists.